The news releases are issued by FUJIFILM Corporation in Japan.
Fujifilm makes no representation that products on these news releases are commercially available in all countries and regions.
Please note that contents in this website are current as of the date of the press announcement and may be subject to change without prior notice. Information in each release, including the product availability, specification, prices, contacts, are those at the time of publication.
- Mar 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Dec 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Dec 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Oct 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Jun 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Apr 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Mar 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product - Sep 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Aug 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
- Jun 29, 2021
- $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
- Jun 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical) - Mar 31, 2021
- FUJIFILM Healthcare starts to operate as Fujifilm Group company
- Mar 30, 2021
- Fujifilm launches “FUJIFILM COVID-19 Ag Test”, a SARS-CoV-2 antigen rapid diagnostic test with a highly-sensitive detection technology based on silver halide amplification, in Europe
- Mar 19, 2021
- Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America
- Feb 18, 2021
- Notice Concerning the Completion Timing for the Acquisition of Hitachi’s Diagnostic Imaging-related Business
- Feb 15, 2021
- Fujifilm Kyowa Kirin Biologics and Mylan EPD Announce Launch of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan
- Jan 29, 2021
- Transfer of Shares in Japan Tissue Engineering Co., Ltd. to TEIJIN LIMITED
- Jan 14, 2021
- Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce 76 million USD in Funding for Manufacturing and Innovation Center
- Jan 7, 2021
- Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
- Jan 5, 2021
- Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility